Michael Toth

Savvy Cooperative was in Princeton today talking to patients and advocates at Johnson & Johnson”s #HealtheVoices24! Want to know what’s on patients minds when it comes to drug #DrugDevelopment #ClinicalTrials #ProtocolDesign Here’s just a FEW things Jen Horonjeff Molly Schreiber and I heard from these amazing patients today- take a listen to just a few seconds of this hour session!! We need to #AskPatients at every point throughout the #DrugDevelopment lifecycle and #Marketing & #Commercialization. Want to know more? Need to get feedback on your #Protocol or #BrandPlanning? Book some time with me! #AskPatients

27

‘If it’s like this, I don’t do it anymore’ (angry stomping) Practicing energy tools for ourselves can sometimes feel that it is failing us. Whether these are for protection, healing, balance, intention setting, realizing our goals etc. it applies to all A/ it is normal, we all go through it, ans some of us are more patient than others. It happened to me many times and that’s then the frustrated and angry Emilie reaction 👆😂 B/ it may not be true that it is failing us, we just don’t see the bigger picture yet. Jeffrey Allen is explaining this very nicely in the below 👇 and giving very helpful tips for when you are in such a situation. Worth watching for those of you that are practicing. Enjoy and keep going! 🌞 #energyhealing #energymanagement #energycoaching

6

🌟 Join me at EXCELerate2024 Conference for a crucial discussion on April 25th from 3:00-4:30pm! 🌟 As we navigate the complexities of modern life, the intersections between our professional and personal spheres become increasingly apparent. That's why I'm thrilled to moderate the upcoming session: "Parallel Paralysis in the Boardroom & the Bedroom: Overcoming the 2 Biggest Barriers to the Successful Pursuit of our Passions​." Our esteemed speakers, Dr. Carolin Klein and Shahana Alibhai, will delve into the parallels between the challenges women face in male-dominated workplaces and those encountered in shame-dominated cultural narratives around sex. From navigating societal expectations to managing stress, shame, and anxiety, we'll explore how these factors impact not only our careers but also our intimate relationships and overall well-being. This session isn't just about identifying barriers; it's about empowering ourselves to overcome them. Together, we'll uncover strategies for breaking free from parallel paralysis and embracing fulfillment in both the boardroom and the bedroom. Don't miss out on this transformative conversation! Mark your calendars for Thursday, April 25th, and join us at EXCELerate2024 Conference in person or virtually. Haven't registered yet? It's not too late... register here: https://lnkd.in/gKy264ci See you there! #Empowerment #CareerSuccess #PersonalGrowth #EXCELerate2024 #WomenInBusiness

7

BMS is poised to enter the Eosinophilic Esophagitis (EoE) market. Buried in the BMS Q2 2024 earnings call was news that company's eosinophilic esophagitis (EoE) treatment, cendakimab, successfully met Phase 3 clinical endpoints. Similar to already-approved, Dupixent, cendakimab is a biologic with subcutaneous injections every other week. Specifics on the data have yet to be released, this new agent could pose some competitive pressure for Dupixent in EoE. #gastroenterology #clinicaldata https://lnkd.in/g_2a2MWv

9

Don't Miss This Episode! 🎧 You survived the DIR Fee Apocalypse… 💥 It's time to step up with a CEO mindset and grow your pharmacy forward! 💪 Catch it this podcast episode now and start making strategic moves today. Listen here: https://lnkd.in/eXqTRqYa #diversifyrx #independentpharmacy #localpharmacy #communitypharmacy #smallpharmacyowner #smallbusinessowner #pharmacy #becomingapharmacybadass #pharmacybadassuniversity

1

Y'all - I love a good quote. Just want to correct the thinking on one. We have all heard, "A jack of all trades is a master of none," right? Well, the quote is incomplete. Full quote - "A jack of all trades is a master of none, but often better than a master of one." Why does it matter? I say I am new to pharma (five years in July), but I have been doing what I do for 22 years. Across multiple industries, including working on healthcare & insurance (CVS and Medicare). Since coming to pharma, I have won multiple awards when I only had honorable mentions or nominations in other verticals. Why so different? Because my approach is new to pharma. Coming from early adopter channels (CPG, Health & Beauty, Travel, Fashion), I pulled through things I had done 10 years prior. That I knew would work. Pharma prioritizes industry over functional experience so there is little opportunity for pharma to catch up. I luckily broke through because Bayer was revolutionizing their approach, but most of the years of experience requirements make this impossible at scale. I am a people-focused marketer. These are the same people buying toothpaste, clothes, vacations, makeup, etc. Why do we expect their behaviors to change for a specific industry? They won't. I am a patient (Crohn's) and I do the same things as a consumer to manage my illness that I do to make other purchase decisions. We talk a lot about the regulatory being a barrier, but I disagree. All ads and channels have a pathway to approval, which I can confirm because we cleared MLR for every new approach. Also, hiring from outside of pharma is good for your DEI initiatives - open up those prospect pools! It is far easier for folks from other industries to transition to pharma than it is in the reverse from a marketing/media skills perspective. Think about it! #pharmamarketing #diversityequityinclusion #dei #digitalmarketing #pharmaceuticals

37

5 Comments

Organon, a global healthcare company with a focus on women’s health, today released its 2023 Environmental, Social and Governance (ESG) Report. “Our achievements in innovation, access and environmental stewardship reflect our unwavering dedication to creating a better and healthier every day for every woman,” said Kevin Ali, Organon CEO. “We are proud of the strides we have made toward our ESG goals. We remain committed to advancing women’s health, ensuring our actions today create a healthier and more equitable future for patients everywhere." Highlights of Organon's progress and achievements across ESG core focus areas include: Advancing Her Equity 👉 Accelerated progress in innovating for women's health: Successfully completed nine transactions, including two in 2023: A strategic investment in Claria Medical, a privately held company developing an investigational medical device being studied for use during minimally invasive laparoscopic procedures; and an agreement with Eli Lilly and Company in Europe aimed at building on strong commercial expertise in central nervous system disorders. 👉 Helped prevent unintended pregnancies: Surpassed the halfway point of the company’s goal to help prevent an estimated 120 million unintended pregnancies by 2030 through the Her Promise Access Initiative. 👉 Advanced gender equity: Female representation in roles at director-level and above increased to 47%, up from 43% three years ago, making progress towards the company’s diversity, equity, inclusion and belonging (DEI&B) goals. Protecting Her Planet 👉 Reduced Scope 1 and 2: Reduced Scope 1 and Scope 2 GHG emissions by 6.6% against a 2020 baseline. To continue these emissions reductions, Organon is entering into a virtual purchase power agreement with Schneider Electric to secure renewable electricity for manufacturing sites in Oss, Netherlands, and Heist, Belgium, for the next 10 years, starting in December 2025. 👉 Exceeded recycling goal: Reused, recycled or otherwise used beneficially 93% of operational waste from Organon’s six manufacturing sites, surpassing the 2025 goal of 80%. Building Her Trust 👉 Maintained gender equity in governance: Maintained a Board composition of nearly 70% women since Organon’s founding in 2021, with two-thirds (66%) of its standing Board committees chaired by women. “Since our launch as an independent company three years ago, we have made significant progress against our ESG commitments and vision to advance the complete health of women at all stages of her life journey,” said Carrie Cox, Chairman, Organon’s Board of Directors. “We believe by advancing the health of women, we advance the health of society. I’m energized by the progress we’ve made and what’s to come as we continue to innovate to improve the lives of women around the world.” 👉 https://lnkd.in/dHy5Z6Um. #ESGreport #Organon #WomensHealth #AdvancingHerEquity #BuildingHerTrust #ProtectingHerPlanet

10

Sema's Founder and CEO Matt Van Itallie joined a recent Pistoia Alliance event in Philadelphia for a presentation and lively discussion on managing the risks of GenAI in Biopharma. Beyond the nearly universal consensus that AI's benefits greatly outweigh the risks, there is also significant uncertainty on which risks matter most and how to tackle them. The presentation and session teased out some of those specifics. Key points: 1-The five major AI Risks for Biopharma come from Inaccuracy, Explainability, Data Privacy and Security, an uncertain Regulatory Environment, and Intellectual Property (IP). 2-On IP Risk, copyright and trade secret risks are the most pertinent but can be managed with the right safeguards. 3-As regulations evolve, biopharma companies should prepare for potential traceability requirements, similar to 21 CFR Part 11 and drug supply chain traceability (DSCSA). GenAI presents immense opportunities for innovation and efficiency in drug discovery, development, and patient care. By proactively addressing these risks, biopharma companies can confidently leverage AI to drive progress and improve health outcomes worldwide. If you'd like to get a copy of the presentation, contact [email protected].

4

I wouldn’t be where I am in my career without the support and advice of strong female mentors. Because of that, I believe in paying it forward by passing along words of wisdom I’ve learned over the years. One particular piece of advice that’s really helped me: Take the time to think about what you really want in your career so that when opportunities arise, you’re ready to advocate for yourself. It’s so important for women to lift each other up, and support each other in realizing their full potential. What advice has helped your career flourish that you can pass along to emerging female leaders? #ConfidenceToBeMe #MerzAesthetics #MedicalAesthetics #WomenInAesthetics #WomenLeaders #MerzAxEmployee

141

14 Comments

Three questions and three actions to help you and your team stay grounded when everything feels uncertain.

11

1 Comment

Happy 4th of July! Today, the United States celebrates Independence Day, a significant holiday that commemorates the country's freedom. One of the most iconic symbols associated with this festive occasion is the American flag, also known as the Stars and Stripes or Old Glory. The flag has a rich history deeply rooted in American culture and holds immense significance. The American flag's origins can be traced back to June 14, 1777, when the Second Continental Congress officially adopted its design. The flag consisted of thirteen alternating red and white stripes, representing the original thirteen colonies, along with a blue field adorned with thirteen white stars, symbolizing a new constellation. As the United States expanded over the years, the flag evolved to incorporate additional stars, each representing a new state. Beyond its visual representation, the American flag carries profound symbolism. It serves as a powerful emblem of national unity, identity, and pride and embodies the fundamental principles upon which the nation was built, such as freedom, democracy, and resilience. #4thofjuly #independenceday #americanflag

27

1 Comment

M&A, Deals, Partnerships: Sanofi completes acquisition of Inhibrx Biosciences, Inc. (San Diego), enhancing its rare disease pipeline with SAR447537, a promising treatment for alpha-1 antitrypsin deficiency (AATD). Inhibrx shareholders approved the acquisition, valued at approximately $1.7 billion. Biotech M&A slumps as drugmakers take a break from public deals. After defying the biggest dealmaking downturn in a decade, Big Pharma is taking a little breather from chasing public companies in favor of smaller, private targets. Drugmakers including Bristol Myers Squibb and AbbVie spent heavily on targets during the later months of last year, often paying hefty premiums in a bid to refresh aging portfolios with new blockbuster medicines. - Sector transaction values cool off after hot streak in 2023 - Big Pharma switches to private deals, with activity up 198% - The value of biotech deals down by more than 40% year-on-year to about $40 billion. IPOs:  Rapport Therapeutics (Boston & SD) announces pricing of IPO. Rapport is a #clinical-stage #biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport announced the pricing of its initial public offering of 8,000,000 shares of its common stock at a public offering price of $17.00 per share. Alumis (South SF) readies IPO to fund rival drug to Bristol Myers Squibb's SOTYKTU™ (deucravacitinib) US HCP. Biotechnology startup Alumis outlined plans for an initial public offering that would fund clinical development of a pair of #autoimmune and #neurological disease drugs. Both medicines are TYK2 inhibitors, a group of oral medicines that drugmakers are positioning as alternatives to injectable #biologics for #inflammatory conditions. FDA Approvals: Eli Lilly and Company Alzheimer’s drug gets unanimous backing of FDA panel. An experimental and closely watched medicine for #Alzheimer’s disease is one step closer to approval, after receiving support from a panel of experts who advise the Food and Drug Administration. The panel unanimously voted that the medicine, developed known as #donanemab, appears to be an effective treatment for certain Alzheimer’s patients. The experts also concluded, by an 11-0 vote, that the drug’s benefits outweigh its risks, despite some safety concerns. Should the agency grant approval, donanemab would be the third Alzheimer’s therapy of its kind cleared for the U.S. market. These medicines work by breaking up sticky, toxic collections of “amyloid beta,” a protein many researchers believe to be a root cause of the memory-robbing disease.

15

Want to learn more about MOMA?

25

Affordable medication is part of Tricia’s plan. Members like Tricia save with CVS Caremark – no coupons, discounts, or rebates needed. Learn more about prescription savings for members without the hassle: https://lnkd.in/ePjPR5M5 #TeamCVS

3

Leaders, what does it look like to finish the year strong? I have 10 ideas that I'll be sharing over the next few days along with a question. I encourage you to answer by commenting on each post so we can learn together. Here's the first idea. As the year comes to a close, it's a great time for leaders to reflect on the past year's achievements and challenges. Take a moment to celebrate your team's successes and learn from the obstacles you've overcome. Is this something you (or your team leader) currently does? What's the format if so? #LeadershipDevelopment #YearEndReflection

15

6 Comments

Fast track for FDA by June 30 will release its verdict on #Rocket Pharmaceuticals’ BLA for #Kresladi (marnetegragene autotemcel), an investigational #gene therapy the New Jersey-based biotech is proposing as a treatment for severe #leukocyte adhesion deficiency-1 (LAD-1). Severe LAD-1 is a rare #pediatric disorder caused by mutations in the #ITGB2 gene, which encodes for a crucial component of the CD18 protein. Under healthy circumstances, #CD18 helps leukocytes exit blood vessels to combat infections. In severe #LAD-1, which typically manifests during early childhood, patients suffer from recurrent and unresponsive bacterial and fungal #infections.

1

Today we raise awareness on Skin Cancer Prevention Month in this month of May. Over 5 million cases have been diagnosed in the US each year and Skin Cancer has been America's most common cancer. Fortunately, skin cancer is one of the most preventable forms of cancer. However, we still want to speak up on the dangers of skin cancer and also share facts and help save lives. #SkinCancer #SkinCancerPrevention #SpeakUp #lifescience

24

2 Comments

check out Chuck's take on the future of Hybrid healthcare.

3

2 Comments